The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis

(2011) Rachel Halpern et al.   Patient Preference and Adherence

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

(2010) Hiangkiat Tan et al.   ADVANCES IN THERAPY

Glatiramer Acetate

(2010) Natalie J. Carter et al.   DRUGS

Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

(2010) Peter J Jongen et al.   Health and Quality of Life Outcomes

The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review

(2010) Ross J. Simpson et al.   Journal of Clinical Lipidology

A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis

(2010) Howard Zwibel et al.   JOURNAL OF NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

(2010) Francesco Patti   Patient Preference and Adherence

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts

(2010) Jane Castelli-Haley et al.   JOURNAL OF MEDICAL ECONOMICS

Medication adherence with disease modifying treatments for multiple sclerosis among US employees

(2010) Nathan L. Kleinman et al.   JOURNAL OF MEDICAL ECONOMICS

Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims

(2010) Benjamin J. Chastek et al.   JOURNAL OF MEDICAL ECONOMICS

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis

(2009) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis

(2009) BD Beretich et al.   Multiple Sclerosis Journal

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

(2008) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Temporal trends in the incidence of multiple sclerosis: A systematic review

(2008) A. Alonso et al.   NEUROLOGY

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH